FDA Determines Regulatory Review Period for NEUROPACE RNS SYSTEM Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of NEUROPACE RNS SYSTEM, a medical device, in accordance with federal regulations and following a submission to the US Patent and Trademark Office (USPTO).